Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Polyclonal Antibody

Anti-Human FGF23 Polyclonal Antibody

Catalog #:   PHJ53401 Specific References (49) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: ELISA, IHC, WB
Accession: Q9GZV9
Overview

Catalog No.

PHJ53401

Species reactivity

Human

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Human FGF23 (Ser180-Ile251).

Tested applications

ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000

Target

Phosphatonin, FGF-23, HYPF, FGF23, Fibroblast growth factor 23, Tumor-derived hypophosphatemia-inducing factor

Purification

Purified by antigen affinity column.

Accession

Q9GZV9

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Data Image
  • Western Blot
    Recombinant Protein lysates were subjected to SDS PAGE followed by western blot with FGF23 antibody (PHJ53401) at 1 µg/ml.

    Lane 1: Recombinant Protein

    Second Ab: Goat Anti-Rabbit IgG H&L Polyclonal antibody, HRP (PTB96431) at 0.1 μg/mL.

    Predict MW: 9 kDa
    Observed MW: 9 kDa
References

Use of burosumab in McCune Albright syndrome: case report and review of literature in mosaic disorders with FGF23 overproduction., PMID:40491596

Burosumab treatment of tumour-induced osteomalacia from a rib lesion., PMID:40379296

Real-world efficacy and safety of burosumab in tumor-induced osteomalacia: case series from an early access program., PMID:40329993

Predictors of response to burosumab in adults with X-linked hypophosphatemia: real-world data from an Italian cohort., PMID:40323576

Real-World Effectiveness of Burosumab Versus Oral Phosphate and Active Vitamin D in Adults With X-Linked Hypophosphatemia., PMID:40314226

Burosumab treatment of a child with McCune-Albright syndrome/polyostotic fibrous dysplasia: challenges and benefits., PMID:40297189

A Child with Cutaneous-Skeletal Hypophosphatemia Syndrome Caused by a Mosaic HRAS Mutation: Outcome of Treatment with Anti-FGF23 Antibody., PMID:40295341

Advancing patient evidence in XLH (APEX): rationale and design of a real-world XLH global data unification program., PMID:40260280

Fibroblast growth factor 23 neutralizing antibody partially rescues bone loss and increases hematocrit in sickle cell disease mice., PMID:40155665

Two Cases of Tumor-induced Osteomalacia Resulting in Surgical Resection During Burosumab Therapy., PMID:40058863

Molecular pathophysiology of chronic kidney disease-mineral and bone disorder: Focus on the fibroblast growth factor 23-Klotho axis and bone turnover dynamics., PMID:40014035

X-Linked Hypophosphataemia and Burosumab: A Systemic Disease With a New Treatment., PMID:40012305

[Rare osteological diseases in the rheumatological consultation: hypophosphatasia and phosphate loss syndromes]., PMID:39982479

Burosumab Treatment in a Girl With Cutaneous Skeletal Hypophosphatemia Syndrome: 2-Year Follow-Up., PMID:39925163

Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia., PMID:39814982

Treatment Advances in Tumor-Induced Osteomalacia., PMID:39755803

Nephrocalcinosis tendency does not worsen under burosumab treatment for X-linked hypophosphatemic rickets: a multicenter pediatric study., PMID:39687707

Protease-activated receptor 2 deficient mice develop less angiotensin II induced left ventricular hypertrophy but more cardiac fibrosis., PMID:39637045

Long-term control by immune checkpoint inhibitors in a lung cancer patient with chronic kidney disease., PMID:39516036

Analytical interference of Burosumab therapy on intact fibroblast growth factor 23 (iFGF23) measurements using an immunoassay: preliminary evaluation., PMID:39494895

Effective bone healing after corrective osteotomy in a patient with FGF23-related hypophosphatemic disease using short-term burosumab treatment., PMID:39375070

Pharmacodynamic Exposure-Response Analysis of Fracture Count Data Following Treatment with Burosumab in Patients with XLH., PMID:39344278

Improvement of Fibrous Dysplasia After Burosumab Therapy in a Pediatric Patient with McCune-Albright Syndrome: A Case Report., PMID:39303050

X-linked hypophosphatemic rickets and nephrocalcinosis: clinical characteristics of a single-center pediatric cohort in North America before and after burosumab., PMID:39156019

NFATc1 Is Required for Vitamin D- and Phosphate-Mediated Regulation of Osteocyte Lacuno-Canalicular Remodeling., PMID:39024412

Burosumab treatment of X-linked hypophosphatemia patients: interim analysis of the SUNFLOWER longitudinal, observational cohort study., PMID:39015507

Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives., PMID:39007037

Molecular Interaction of Soluble Klotho with FGF23 in the Pathobiology of Aortic Valve Lesions Induced by Chronic Kidney Disease., PMID:38993571

Multiarray screening identifies plasma proteins associated with Th17 cell differentiation and viral defense in coincident asthma and obesity., PMID:38967090

Safety and efficacy of burosumab in improving phosphate metabolism, bone health, and quality of life in adolescents with X-linked hypophosphatemic rickets., PMID:38950880

Improved Oral Health in Adults With X-Linked Hypophosphatemia Treated With Burosumab., PMID:38864457

Cardiovascular health in pediatric patients with X-linked hypophosphatemia under two years of burosumab therapy., PMID:38818505

Interplay of clinical biomarkers in allergic asthma diagnosis and severity: A case-control study., PMID:38814233

Efficacy and safety of burosumab compared with conventional therapy in patients with X-linked hypophosphatemia: A systematic review., PMID:38788147

Real-world non-interventional post-authorization safety study of long-term use of burosumab in children and adolescents with X-linked hypophosphatemia: first interim analysis., PMID:38764445

Non-Classical Effects of FGF23: Molecular and Clinical Features., PMID:38732094

S100a8/9 (S100 Calcium Binding Protein a8/9) Promotes Cardiac Hypertrophy Via Upregulation of FGF23 (Fibroblast Growth Factor 23) in Mice., PMID:38726894

Recent advances in fibroblast growth factor 23-related hypophosphatemic disorders., PMID:38687287

The hidden cross talk between bone and tissues through bone turnover., PMID:38634076

Cardiac and Renal Fibrosis, the Silent Killer in the Cardiovascular Continuum: An Up-to-Date., PMID:38392276

In chronic kidney disease altered cardiac metabolism precedes cardiac hypertrophy., PMID:38385175

Hypocalcemia and Hypophosphatemia following Concurrent Denosumab Injection and Ferric Carboxymaltose Infusion in a Patient with Normal Renal Function., PMID:38343603

Rickets Types and Treatment with Vitamin D and Analogues., PMID:38337700

Real-world data of Brazilian adults with X-linked hypophosphatemia (XLH) treated with burosumab and comparison with other worldwide cohorts., PMID:38337160

Burosumab for the treatment of cutaneous-skeletal hypophosphatemia syndrome., PMID:38229908

FGF23-related hypophosphatemic rickets preceding the onset of systemic lupus erythematosus: A juvenile case., PMID:38223518

Successful Burosumab Treatment in an Adult Patient with X-Linked Hypophosphatemia and Chronic Kidney Disease Stage 3b., PMID:38195892

Spectrum of PHEX Mutations and FGF23 Profiles in a Taiwanese Cohort With X-Linked Hypophosphatemia Including 102 Patients., PMID:38148081

The pathophysiology of hypophosphatemia., PMID:38087658

Datasheet
$ 170
Product specifications
50 μg 170 100 μg 280

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Human FGF23 Polyclonal Antibody [PHJ53401]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only